Ciara Freeman, MD, PhD

  Dr. Ciara Freeman is an Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy. She obtained her MD from the National University of Ireland, specialised in hematology at St Bartholomew’s in London and obtained a master’s degree in Clinical Drug Development from Queen Mary University of London (QMUL). She also earned her PhD in immuno-oncology and therapeutics from the Barts Cancer Institute of QMUL under Professor John Gribben. She completed a fellowship in lymphoproliferative disorders and joins us from the British Columbia Cancer Agency in Vancouver, Canada, where she served as Assistant Professor and the Myeloma Lead. Her clinical interests are focused on the treatment of patients with plasma cell neoplasms using autologous transplant and cellular immunotherapy. Her research interests are centred on optimising outcomes for patients using this novel approach – identifying predictors of treatment failure or toxicity, new target discovery and clinical trial development, in addition to identifying the best modalities for measuring disease burden and relapse. She is also interested in how to safely administer these highly effective and personalised cell therapies to all patients, including those with additional health concerns. Dr Freeman’s research has been acknowledged with awards from the American Society of Hematology and she is deeply motivated to translate clinical and laboratory experience to deepen our understanding so that patients can universally benefit from this novel approach to treating myeloma.  

Associations

• Blood and Marrow Transplant and Cellular Immunotherapy
• Immuno-Oncology Program

Education & Training

Graduate:

• Barts Cancer Institute of QMUL, PhD - Immuno-Oncology
• Queen Mary University of London, MSc - Clinical Drug Development

Fellowship:

• Barts and the Royal London NHS Trust - Hematology
• BC Cancer Centre - lymphoproliferative disorders

Residency:

• Mater Misercordiae Hospital, Dublin -
• Mayo Clinic, Scottsdale Arizona -

Medical School:

• National University of Ireland - MD

  Dr. Ciara Freeman is an Assistant Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy. She obtained her MD from the National University of Ireland, specialised in hematology at St Bartholomew’s in London and obtained a master’s degree in Clinical Drug Development from Queen Mary University of London (QMUL). She also earned her PhD in immuno-oncology and therapeutics from the Barts Cancer Institute of QMUL under Professor John Gribben. She completed a fellowship in lymphoproliferative disorders and joins us from the British Columbia Cancer Agency in Vancouver, Canada, where she served as Assistant Professor and the Myeloma Lead. Her clinical interests are focused on the treatment of patients with plasma cell neoplasms using autologous transplant and cellular immunotherapy. Her research interests are centred on optimising outcomes for patients using this novel approach – identifying predictors of treatment failure or toxicity, new target discovery and clinical trial development, in addition to identifying the best modalities for measuring disease burden and relapse. She is also interested in how to safely administer these highly effective and personalised cell therapies to all patients, including those with additional health concerns. Dr Freeman’s research has been acknowledged with awards from the American Society of Hematology and she is deeply motivated to translate clinical and laboratory experience to deepen our understanding so that patients can universally benefit from this novel approach to treating myeloma.  

Clinical Trial 23135
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Condition: Malignant Hematology
Intervention: BMS-986393 (); Tocilizumab (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Status: Open

Clinical Trial 23321
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Anitocabtagene autoleucel (); Bortezomib (); CC-4047 (Pomalidomide); Daratumumab (Darzalex); Dexamethasone (); PS-341 (Bortezomib); Pomalidomide (); Velcade (Bortezomib); carfilzomib (Kyprolis); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Status: Open

Clinical Trial 23711
Artificial Intelligence-Integrated Clinical, Pathologic, Genomic, and Radiologic Model for Predicting Response to Complex Immunotherapies and Risk of Developing Extramedullary Disease in Multiple Myeloma
Condition: Malignant Hematology
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Meads MB, Zhao X, Noyes DR, Sudalagunta P, Achille A, Zhang C, Renatino Canevarolo R, Silva M, Magaletti D, DeAvila D, Toska S, Oates A, Lastorino D, Idiaquez DW, Song J, Sansil S, Yoder SJ, Grajales-Cruz AF, Blue BJ, Freeman CL, Kim J, Alsina M, Brayer J, Siqueira Silva A, Song X, Shain KH, Baz RC. Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy. Blood. 2025 Sep. Pubmedid: 40983035.
• Huynh THN, Clampitt BA, Chose CM, Nester MD, Joyce DM, Binitie OT, Freeman CL, Lazarides AL. Influence of Chimeric Antigen Receptor T-Cell Therapy on Fracture Risk of Patients With Multiple Myeloma. J Am Acad Orthop Surg. 2025 Sep. Pubmedid: 40953403.
• Sweiss K, Wagner C, Anto E, Greene T, Sun R, Gonzalez R, Puglianini OC, Freeman C, Ionescu F, Patel K, Ferreri C, Gaballa M, Shune L, McGuirk J, Sidana S, Hovanky V, Khouri J, Raza S, Anwer F, Dima D, Hashmi H, Davis J, Afrough A, Kaur G, Anderson JL, Forsberg P, Herr M, Hansen DK, Hakan Kocoglu M, Sborov D. Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium. Transplant Cell Ther. 2025 Sep. Pubmedid: 40972962.
• Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025 Oct.146(17):2063-2072. Pubmedid: 40749169.
• Di Meo F, Albano F, Cesarano A, Wang Y, Kale B, Shain K, Silva A, Kurihara N, Tenshin H, Jellyman D, Song X, Ghaffari S, Mesa H, Creelan B, Freeman C, Zhao X, Meads MB, Rodriguez PC, Marino S, Locke F, Hwu P, Roodman D, Mansilla-Soto J, Perna F. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell. 2025 Oct. Pubmedid: 41072416.
• Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez M, Sannareddy A, Goel U, Banerjee R, Khouri J, Cervoni F, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune L, DeJarnette S, Bhurtel E, Susanibar Adaniya S, Portuguese A, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Midha S, Omar N, Atarsh S, McGuirk J, Sborov D, Voorhees P, Anwer F, Alsina M, Freeman C, Garfall AL, Razzo BM, Sidana S, Cowan AJ, Anderson LD, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A. Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2025 May.15(1):92. Pubmedid: 40346049. Pmcid: PMC12064690.
• Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD, Richard S, Martin T, Lin Y, Patel KK, Sidana S. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2025 May.43(13):1597-1609. Pubmedid: 39965175. Pmcid: PMC12037312.
• Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Ouchveridze E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar AD, Liu Y, Locke FL, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD, Cowan AJ, Kaur G. Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Adv. 2025 May.9(9):2336-2340. Pubmedid: 40088469. Pmcid: PMC12127628.
• Henning JE, Nishihori T, Freeman C, Lazarides A, Song J, Kuruvilla D, Feuerlein S, Costello JR. Whole-body MRI for a patient with progressive multiple myeloma. BJR Case Rep. 2025 May.11(3):uaaf028. Pubmedid: 40386466. Pmcid: PMC12085220.
• Freeman CL, Srinivasan S, Hodkinson B, Deshpande S, Henninger T, Boyle M, Wang ML, Dreyling M, Scott DW. Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status. Blood. 2025 Jun.145(25):3052-3056. Pubmedid: 40101138.
• Jhaveri K, Thapa R, Ercan D, Saha A, Noble J, Singh P, Fahrmann J, Saini N, Wu R, Dennison JB, Hanash S, Jenq RR, Modi K, Figura N, Chavez J, Shah B, Nishihori T, Lazaryan A, Khimani F, Bachmeier C, Gage K, Mishra A, Perna F, Davila ML, Spiegel J, Rejeski K, Subklewe M, Locke FL, Freeman C, Parker N, Jain MD. Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2025 Jul.31(13):2756-2766. Pubmedid: 40238583. Pmcid: PMC12213223.
• Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK. Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma. Haematologica. 2025 Jul. Pubmedid: 40637727.
• Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, Hansen DK, Ferreri CJ, Freeman CL, Afrough A, Anderson LD, Dhakal B, Dhanda DS, Gowda L, Hashmi H, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patwardhan P, Qazilbash MH, Usmani SZ, Patel KK, Nishihori T, Ganguly S, Pasquini MC. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jul.146(2):167-177. Pubmedid: 40198886.
• Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025 Jan.145(1):85-97. Pubmedid: 39365257.
• Alduaij W, Jiang A, Villa D, Collinge BJ, Ben-Neriah S, Boyle M, Meissner B, Hilton LK, Farinha P, Slack GW, Craig JW, Gerrie AS, Freeman CL, Mungall AJ, Steidl C, Sehn LH, Scott DW, Savage KJ. CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL. Blood. 2025 Feb.145(6):590-596. Pubmedid: 39441916.
• Freeman CL, Abraham-Miranda J, Menges M, Atkins RM, Noble J, Liu H, Corallo S, Cuadrado Delgado LA, Ribickas AJ, Savid-Frontera C, de Avila G, Castaneda Puglianini OA, Ochoa-Bayona J, Hansen DK, Alsina M, Baz R, Nishihori T, Shain KH, Locke FL. Enhanced CAR-T cell function and mitochondrial fitness from earlier unfractionated stem cell product in multiple myeloma. Mol Ther. 2025 Aug.33(8):3576-3589. Pubmedid: 40253586. Pmcid: PMC12461620.
• Palfi S, Peres LC, Koelmeyer H, Alsina M, Baz RC, Blue BJ, Corallo S, De Avila G, Freeman C, Gonzalez R, Grajales-Cruz A, Harvey K, Liu HD, Nishihori T, Oliveira GH, Oswald LB, Castaneda Puglianini O, Selvakumar S, Sharma AB, Wang E, Shain KH, Jain M, Locke FL, Alomar M, Hansen DK, Lee DH. Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma. Blood Cancer J. 2025 Apr.15(1):63. Pubmedid: 40229239. Pmcid: PMC11997198.
• Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, Tonseth RP, Idiaquez DW, Skelson L, Smith EC, Abraham-Miranda J, Corallo S, De Avila G, Castaneda Puglianini O, Liu HD, Alsina M, Nishihori T, Shain KH, Baz RC, Blue BJ, Grajales-Cruz A, Koomen JM, Atkins RM, Hansen DK, Siqueira Silva A, Kim J, Balagurunathan Y, Locke FL. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025 Apr.145(15):1645-1657. Pubmedid: 39652773.
• Banerjee R, Fritz AR, Akhtar OS, Freeman CL, Cowan AJ, Shah N, Landau HJ, Kumar SK, Vogl DT, Efebera YA, McCarthy PL, Vesole DH, Mendizabal A, Krishnan AY, Somlo G, Stadtmauer EA, Pasquini MC. Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702. Leukemia. 2025 Apr.39(4):1001-1004. Pubmedid: 39994463. Pmcid: PMC11978488.
• Akhtar OS, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, Ahmed N, Bye M, Hansen DK, Ferreri CJ, Dhakal B, Dhanda DS, Harrison MJ, Kitali A, Landau HJ, Mirza AS, Patel J, Patwardhan P, Qazilbash MH, Patel KK, Nishihori T, Ganguly S, Gowda L, Anderson LD, Pasquini MC, Usmani SZ, Freeman CL. Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study. Blood Adv. 2025 Apr.9(7):1587-1592. Pubmedid: 39786391. Pmcid: PMC11986210.
• Kuruvilla D, Huynh T, Nester M, Chose C, Zervoudakis G, Letson GD, Joyce DM, Binitie OT, Figura NB, Costello JR, Freeman CL, Lazarides AL. Management of bone disease with concurrent chimeric antigen receptor T-cell therapy for multiple myeloma. Crit Rev Oncol Hematol. 2024 Sep.201:104429. Pubmedid: 38942219.
• Kalariya N, Hildebrandt MAT, Hansen DK, Sidana S, Khouri J, Ferreri CJ, Doyle WN, Castaneda Puglianini OA, Freeman CL, Hovanky V, Hosoya H, Shune L, Patel KK. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024 Sep.8(17):4679-4688. Pubmedid: 39042903. Pmcid: PMC11402173.
• Handley G, Yepes A, Eliassen E, Dominguez G, Pasikhova Y, Klinkova O, Baluch A, Febres-Aldana AJ, Alsina M, Elmariah H, Khimani F, Hansen DK, Freeman CL, Jain MD, Locke F, Lazaryan A, Liu HD, Mishra A, Mirza AS, Nishihori T, Ochoa L, Perez L, Pidala J, Puglianini OC, Nieder M, Perna F, Kim J, Bejanyan N, Faramand R. Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation. Open Forum Infect Dis. 2024 Oct.11(10):ofae564. Pubmedid: 39411216. Pmcid: PMC11475747.
• Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience. Haematologica. 2024 May.109(5):1514-1524. Pubmedid: 37855036. Pmcid: PMC11063864.
• Akhtar OS, Modi K, Kim J, Skellson L, Smith E, Al-Jumayli MA, Extermann M, De Avila G, Parker N, Castaneda-Puglianini O, Grajales-Cruz A, Baz R, Blue B, Shain K, Alsina M, Liu H, Nishihori T, Jain MD, Locke FL, Hansen DK, Freeman CL. Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy. Transplant Cell Ther. 2024 Mar.30(3):283.e1-283.e10. Pubmedid: 38123069.
• Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2024 Mar.109(3):777-786. Pubmedid: 37731379. Pmcid: PMC10905101.
• Akhtar OS, Sheeba BA, Azad F, Alessi L, Hansen D, Alsina M, Baz R, Shain K, Grajales Cruz A, Castaneda Puglianini O, Liu H, Blue B, Nishihori T, Al Jumayli M, Extermann M, Locke FL, Mhaskar R, Freeman CL. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis. Geriatr Oncol. 2024 Mar.15(2):101628. Pubmedid: 37723045.
• Kim JL, Gerrie AS, Savage KJ, Villa D, Scott D, Craig JW, Farinha P, Skinnider B, Slack G, Connors JM, Sehn LH, Venner C, Freeman CL. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based a. Leuk Lymphoma. 2024 Mar.65(3):346-352. Pubmedid: 38156444.
• Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024 Jun.17(1):42. Pubmedid: 38845015. Pmcid: PMC11157748.
• Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini OA, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri CJ, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees PM, Khouri J, McGuirk JP, Sidana S, Hansen DK, Patel KK. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 Jan.8(1):251-259. Pubmedid: 37855718.
• Verbruggen SW, Freeman CL, Freeman FE. Utilizing 3D Models to Unravel the Dynamics of Myeloma Plasma Cells' Escape from the Bone Marrow Microenvironment. Cancers (Basel). 2024 Feb.16(5). Pubmedid: 38473251. Pmcid: PMC10931336.
• Yohay S, Oloyede T, Kim S, Fang X, Dhakal B, Aijaz A, Mohan M, Narra R, Pasquini M, D'Souza A, Hamadani M, Freeman CL, Akhtar OS. Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma. Brit J Haematol. 2024 Dec.205(6):2370-2375. Pubmedid: 39396814.
• Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, Dima D, Freeman CL, Puglianini OC, Kocoglu MH, Atrash S, Voorhees PM, Shune L, McGuirk JP, Simmons G, Sborov DW, Davis JA, Kaur G, Sannareddy A, Ferreri CJ, Gaballa MR, Goldsmith S, Nadeem O, Midha S, Wagner CB, Locke FL, Patel KK, Khouri J, Anderson LD, Lin Y. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024 Apr.14(1):63. Pubmedid: 38609386. Pmcid: PMC11015040.
• Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel. Cancers (Basel). 2023 Sep.15(19). Pubmedid: 37835405. Pmcid: PMC10571575.
• Freeman CL, Locke FL. CARs put age in the rearview mirror. Blood. 2023 Sep.142(12):1029-1031. Pubmedid: 37733380.
• Hilton LK, Ngu HS, Collinge B, Dreval K, Ben-Neriah S, Rushton CK, Wong JCH, Cruz M, Roth A, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Freeman CL, Villa D, Rodrigo JA, Song K, Crump M, Shepherd L, Hay AE, Kuruvilla J, Savage KJ, Kridel R, Karsan A, Marra MA, Sehn LH, Steidl C, Morin RD, Scott DW. Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2023 Sep.41(25):4164-4177. Pubmedid: 37319384.
• Akhtar OS, Cao B, Wang X, Torka P, Al-Jumayli M, Locke FL, Freeman CL. CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response. Blood Adv. 2023 Oct.7(19):5937-5940. Pubmedid: 37236167. Pmcid: PMC10562759.
• Freeman CL, Atkins R, Varadarajan I, Menges M, Edelman J, Baz R, Brayer J, Castaneda Puglianini O, Ochoa-Bayona JL, Nishihori T, Shain KH, Shah B, Chen DT, Kelley L, Coppola D, Alsina M, Antonia S, Anasetti C, Locke FL. Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. Clin Cancer Res. 2023 Nov.29(22):4575-4585. Pubmedid: 37735756.
• Alduaij W, Collinge BJ, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, Meissner B, Chong LC, Miyata-Takata T, Slack GW, Farinha P, Craig JW, Lytle A, Savage KJ, Villa D, Gerrie AS, Freeman CL, Gascoyne RD, Connors JM, Morin RD, Sehn LH, Mungall AJ, Steidl C, Scott DW. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population. Blood. 2023 May.141(20):2493-2507. Pubmedid: 36302166.
• Hilton LK, Ngu HS, Collinge B, Dreval K, Ben-Neriah S, Rushton CK, Wong JCH, Cruz M, Roth A, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Gerrie AS, Freeman CL, Villa D, Crump M, Shepherd L, Hay AE, Kuruvilla J, Savage KJ, Kridel R, Karsan A, Marra MA, Sehn LH, Steidl C, Morin RD, Scott DW. Relapse timing is associated with distinct evolutionary dynamics in DLBCL. medRxiv. 2023 Mar. Pubmedid: 36945587. Pmcid: PMC10029038.
• Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023 Jul.16(1):88. Pubmedid: 37525244. Pmcid: PMC10391746.
• Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
• Villa D, Hoster E, Hermine O, Klapper W, Szymczyk M, Bosly A, Unterhalt M, Rimsza LM, Ramsower C, Freeman CL, Scott DW, Gerrie AS, Savage KJ, Sehn LH, Dreyling M. Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. Blood Adv. 2022 Sep.6(18):5285-5294. Pubmedid: 35439293. Pmcid: PMC9631687.
• Jessa R, Chien N, Villa D, Freeman CL, Slack GW, Savage KJ, Scott DW, Sehn LH, Song KW, Gerrie AS. Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia. Brit J Haematol. 2022 Oct.199(2):230-238. Pubmedid: 35961783.
• Freeman CL, Pararajalingam P, Jin L, Balasubramanian S, Jiang A, Xu W, Grau M, Zapukhlyak M, Boyle M, Hodkinson B, Schaffer M, Enny C, Deshpande S, Sun S, Vermeulen J, Morin RD, Scott DW, Lenz G. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. Leukemia. 2022 Oct.36(10):2479-2487. Pubmedid: 35963941.
• Wang X, Nissen M, Gracias D, Kusakabe M, Simkin G, Jiang A, Duns G, Sarkozy C, Hilton L, Chavez EA, Segat GC, Wong R, Kim J, Aoki T, Islam R, May C, Hung S, Tyshchenko K, Brinkman RR, Hirst M, Karsan A, Freeman C, Sehn LH, Morin RD, Roth AJ, Savage KJ, Craig JW, Shah SP, Steidl C, Scott DW, Weng AP. Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk. Nat Commun. 2022 Nov.13(1):6772. Pubmedid: 36351924. Pmcid: PMC9646774.
• Cheng PTM, Villa D, Gerrie AS, Freeman CL, Slack GW, Gascoyne RD, Farinha P, Craig JW, Skinnider B, Wilson D, Scott DWW, Connors JM, Sehn LH, Savage KJ. The outcome of older adults with classic Hodgkin lymphoma in British Columbia. Blood Adv. 2022 Nov.6(22):5924-5932. Pubmedid: 36075016. Pmcid: PMC9701622.
• Chahal M, Hayden A, Savage KJ, Villa D, Scott DW, Gerrie AS, Lo A, Chan M, Pickles T, Connors JM, Sehn LH, Freeman CL. Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma. Leuk Lymphoma. 2022 Nov.63(11):2739-2742. Pubmedid: 35749607.
• Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 Dec.28(12):829.e1-829.e8. Pubmedid: 36174934. Pmcid: PMC9791940.
• Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
• Pawlyn C, Khan AM, Freeman CL. Fitness and frailty in myeloma. Hematology Am Soc Hematol Educ Program. 2022 Dec.2022(1):337-348. Pubmedid: 36485137. Pmcid: PMC9820647.
• Zhu K, Jamroz A, Huang S, Villa D, Freeman CL, Scott DW, Slack G, Sehn LH, Connors JM, Toze CL, Savage KJ, Gerrie AS. Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia. Brit J Haematol. 2022 Aug.198(4):684-692. Pubmedid: 35567407.
• Cheng PTM, Villa D, Tonseth RP, Scott DW, Gerrie AS, Freeman CL, Pickles T, Lo AC, Farinha P, Craig JW, Slack GW, Gascoyne RD, Bénard F, Wilson D, Skinnider B, Connors JM, Sehn LH, Savage KJ. Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. Blood Adv. 2021 Sep.5(18):3647-3655. Pubmedid: 34438445. Pmcid: PMC8945586.
• Moccia AA, Schaff K, Freeman C, Hoskins PJ, Klasa RJ, Savage KJ, Shenkier TN, Gascoyne RD, Connors JM, Sehn LH. Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. Blood Adv. 2021 Mar.5(5):1483-1489. Pubmedid: 33683338. Pmcid: PMC7948286.
• Freeman CL, Savage KJ, Villa DR, Scott DW, Srour L, Gerrie AS, Brown MJ, Slack GW, Farinha P, Skinnider B, Morris J, Bénard F, Aquino-Parsons C, Lo A, Pickles T, Wilson DC, Tonseth P, Connors JM, Sehn LH. Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2021 Feb.137(7):929-938. Pubmedid: 32871586.
• Raymakers AJN, Regier DA, Peacock SJ, Freeman CL. Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials. J Cancer Policy. 2021 Dec.30:100304. Pubmedid: 35559800.
• Grant SJ, Freeman CL, Rosko AE. Treatment of older adult or frail patients with multiple myeloma. Hematology Am Soc Hematol Educ Program. 2021 Dec.2021(1):46-54. Pubmedid: 34889397. Pmcid: PMC8791156.
• Urban R, Chow R, Pickles T, Chan M, Livergant J, Gerrie AS, Freeman C, Sehn L, Scott DW, Villa D, Farinha P, Gondara L, Savage KJ, Lo AC. The impact of surveillance imaging after curative-intent radiotherapy for limited-stage follicular lymphoma. Brit J Haematol. 2021 Dec.195(5):802-805. Pubmedid: 34734418.
• Lo AC, Chen B, Samuel V, Savage KJ, Freeman C, Goddard K. Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis. J Cancer Surviv. 2021 Dec.15(6):837-846. Pubmedid: 33453004.
• Collinge B, Ben-Neriah S, Chong L, Boyle M, Jiang A, Miyata-Takata T, Farinha P, Craig JW, Slack GW, Ennishi D, Mottok A, Meissner B, Chavez EA, Gerrie AS, Villa D, Freeman C, Savage KJ, Sehn LH, Morin RD, Mungall AJ, Gascoyne RD, Marra MA, Connors JM, Steidl C, Scott DW. The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. Blood. 2021 Apr.137(16):2196-2208. Pubmedid: 33120427.
• Lo AC, Samuel V, Chen B, Savage KJ, Freeman C, Goddard K. Evaluation of the discussion of late effects and screening recommendations in survivors of adolescent and young adult (AYA) lymphoma. J Cancer Surviv. 2021 Apr.15(2):179-189. Pubmedid: 32767044.
• Freeman CL, Mikhael J. COVID-19 and myeloma: what are the implications for now and in the future?. Brit J Haematol. 2020 Jul.190(2):173-178. Pubmedid: 32428242. Pmcid: PMC7276733.
• Freeman CL, Sehn LH. Initial Treatment of High Tumor Burden Follicular Lymphoma. Hematol Oncol Clin North Am. 2020 Aug.34(4):673-687. Pubmedid: 32586573.
• Villa D, Sehn LH, Savage KJ, Toze CL, Song K, den Brok WD, Freeman CL, Scott DW, Gerrie AS. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Blood Adv. 2020 Aug.4(15):3486-3494. Pubmedid: 32735654. Pmcid: PMC7422137.
• Freeman CL, Kridel R, Moccia AA, Savage KJ, Villa DR, Scott DW, Gerrie AS, Ferguson D, Cafferty F, Slack GW, Farinha P, Skinnider B, Connors JM, Sehn LH. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019 Aug.134(9):761-764. Pubmedid: 31300404.
• Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, Collinge B, Abrisqueta P, Farinha P, Boyle M, Meissner B, Kridel R, Gerrie AS, Villa D, Savage KJ, Sehn LH, Siebert R, Morin RD, Gascoyne RD, Marra MA, Connors JM, Mungall AJ, Steidl C, Scott DW. High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. Blood Adv. 2018 Oct.2(20):2755-2765. Pubmedid: 30348671. Pmcid: PMC6199666.
• Freeman CL, Sehn L. Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?. Curr Oncol Rep. 2018 Nov.20(12):103. Pubmedid: 30483893.
• Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Brit J Haematol. 2018 Jul.182(1):29-45. Pubmedid: 29741753.
• Breen DP, Freeman CL, De Silva RN, Derakhshani S, Stevens J. Soft tissue plasmacytomas in multiple myeloma. Lancet. 2017 Nov.390(10107):2083. Pubmedid: 28844475.
• Freeman CL, Gribben JG. Immunotherapy in Chronic Lymphocytic Leukaemia (CLL). Curr Hematol Malig Rep. 2016 Feb.11(1):29-36. Pubmedid: 26857283. Pmcid: PMC4796351.
• Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, Humphrey K, Böttcher S, de Costa CS, Iglesias V, Stilgenbauer S, Gribben J, Hallek M, Goede V. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 2016 Aug.30(8):1763-1766. Pubmedid: 26979130. Pmcid: PMC4980557.
• Kim YY, Carloni JD, Demarchi B, Sparks D, Reid DG, Kunitake ME, Tang CC, Duer MJ, Freeman CL, Pokroy B, Penkman K, Harding JH, Estroff LA, Baker SP, Meldrum FC. Tuning hardness in calcite by incorporation of amino acids. Nat Mater. 2016 Aug.15(8):903-910. Pubmedid: 27135858.
• Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E, Gribben JG, Hallek M, Salles G, Cartron G. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015 Dec.126(24):2646-2649. Pubmedid: 26447188. Pmcid: PMC4671111.
• Giles FJ, Krawczyk J, O'Dwyer M, Swords R, Freeman C. The role of inflammation in leukaemia. Adv Exp Med Biol. 2014 May.816:335-360. Pubmedid: 24818729.
• Krawczyk J, Keane N, Swords R, O'Dwyer M, Freeman CL, Giles FJ. Perifosine--a new option in treatment of acute myeloid leukemia?. Expert Opin Inv Drug. 2013 Oct.22(10):1315-1327. Pubmedid: 23931614.
• Krawczyk J, Keane N, Freeman CL, Swords R, O'Dwyer M, Giles FJ. 5-Azacytidine for the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2013 Jun.14(9):1255-1268. Pubmedid: 23621771.
• Freeman C, Keane N, Swords R, Giles F. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?. Expert Opin Pharmacother. 2013 Jul.14(10):1417-1427. Pubmedid: 23688047.
• Keane N, Freeman C, Swords R, Giles FJ. Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia. Expert Rev Hematol. 2013 Feb.6(1):9-24. Pubmedid: 23373775.
• Swords R, Freeman C, Giles F. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Leukemia. 2012 Oct.26(10):2176-2185. Pubmedid: 22614177.
• Keane N, Freeman C, Swords R, Giles FJ. EPHA3 as a novel therapeutic target in the hematological malignancies. Expert Rev Hematol. 2012 Jun.5(3):325-340. Pubmedid: 22780212.
• Freeman CL, Swords R, Giles FJ. Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?. Expert Rev Hematol. 2012 Feb.5(1):17-26. Pubmedid: 22272701.
• Jimenez-Zepeda VH, Heilman RL, Engel RA, Carey EJ, Freeman C, Rakela J, Mulligan DC, Fonseca R, Stewart AK. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation. 2011 Sep.92(5):570-574. Pubmedid: 21712755.

• Title: Geriatric Oncology Research Infrastructure to Improve Clinical Care
  Award Number: R33AG059206-07
  Sponsor: National Institutes of Health (NIH)
  Freeman, C. (PD/PI)
• Title: Development of a novel, non-BCMA targeting CAR-T cell therapy for the treatment of multiple
  Award Number: 09334422601
  Sponsor: Pentecost Mult Myeloma
  Freeman, C. (PD/PI)
• Title: Development of a novel, non-BCMA targeting CAR-T cell therapy for the treatment of multiple myeloma
  Award Number:
  Sponsor: Foundation Support-Rsch
  Binning, J. (PD/PI), Freeman, C. (PD/PI)